An analytical method for polysaccharides on single extracellular vesicles

By employing magnetic nanoparticle capture and fluorescent labeling techniques, this method overcomes the problem in existing technologies where extracellular vesicular glycan analysis cannot identify signal differences between individuals, achieving high-sensitivity and high-throughput detection of single extracellular vesicular glycans, which is applicable to fields such as early cancer diagnosis.

CN117269124BActive Publication Date: 2026-11-17WENZHOU INST UNIV OF CHINESE ACAD OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311029628.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-15
Publication Date
2026-11-17
Estimated Expiration
2043-08-15

AI Technical Summary

Technical Problem

In existing technologies, extracellular vesicle glycan analysis methods cannot effectively identify differences in glycan signals between different vesicle individuals, thus limiting their application in early cancer detection.

Method used

Magnetic nanoparticles were used to capture single extracellular vesicles, and biotin-modified lectins were used for affinity labeling. The lectins were then bound to streptavidin modified with fluorescein, and image data were acquired using a fluorescence microscope to determine the degree of glycan expression.

Benefits of technology

It achieves highly sensitive detection of glycans on individual extracellular vesicles, can show the differences in glycan signals between individual vesicles, has high detection throughput, low cost and simple operation, and is suitable for conventional fluorescence microscopy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117269124B_ABST
    Figure CN117269124B_ABST
Patent Text Reader

Abstract

This invention discloses an analytical method for glycans on single extracellular vesicles. The method includes: first, capturing single extracellular vesicles in a sample using magnetic nanoparticles, followed by magnetic separation to obtain a magnetic nanoparticle complex; then, affinity labeling the glycans on the extracellular vesicles within the magnetic nanoparticle complex using biotin-modified lectin, followed by binding with fluorescein-modified streptavidin to obtain fluorescently labeled magnetic complex particles; finally, acquiring image data and fluorescence signal data of the fluorescently labeled magnetic complex particles using a fluorescence microscope, and determining the glycan expression level on the extracellular vesicles based on the fluorescence intensity of a single fluorescently labeled magnetic complex particle. This method offers superior detection sensitivity compared to holistic analysis methods, effectively revealing the differences in glycan signals among different extracellular vesicle individuals, and enabling the detection of glycan expression heterogeneity among extracellular vesicle individuals.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to a method for analyzing polysaccharides on single extracellular vesicles. Background Technology

[0002] Extracellular vesicles (EVs) are a collective term for double-membrane-structured particles released by cells. Based on their secretion mechanisms and physical properties, they can be broadly classified into different subtypes, including exosomes (30–150 nm in diameter), microvesicles (100–1000 nm in diameter), and apoptotic bodies (50–5000 nm in diameter). EVs possess stable and non-replicating closed vesicular structures and are widely present in various body fluids such as blood, urine, saliva, tears, breast milk, and ascites. They can reflect multiple biological information from their parent cells or tissues and play important roles in various physiological and pathological processes, including intercellular communication, immune regulation, angiogenesis, cell migration, and the development of cancer. Based on these characteristics, EVs have shown broad application prospects in many fields, including disease diagnosis (such as early cancer screening), drug delivery, inflammation regulation, and medical aesthetics.

[0003] The broad biological functions and clinical application potential of EVs are primarily based on their constituent biological molecular components. Related studies have shown that EVs carry a rich array of contents, such as proteins, lipids, nucleic acids, and small metabolic molecules. Notably, recent research has revealed that, in addition to the aforementioned components, EVs also contain various glycosyl compounds, such as O-glycans, N-glycans, and glycolipid gangliosides, which participate in multiple biological processes including cell recognition, viral infection, development and differentiation, and immune responses. Furthermore, research indicates that EV glycans can also serve as diagnostic biomarkers for liquid biopsies in cancer. For example, the research by Raghu Kalluri's team at the University of Texas MD Anderson Cancer Center suggests that the proteoglycan Glypican-1 on plasma EVs has the potential to be used as a target tool for the early diagnosis and monitoring of pancreatic cancer; and the preliminary evidence from Shao Huilin's team at the National University of Singapore demonstrates the promising application prospects of EV glycans in assessing the prognosis of patients with gastric and colorectal cancer. However, to fully explore the important role of EV glycans in physiological and pathological processes and their clinical application potential, in-depth and accurate analysis is essential.

[0004] In related technologies, most EV glycan analysis methods analyze vesicle samples as a whole, such as liquid chromatography, mass spectrometry, lectin microarray, enzyme-linked immunosorbent assay (ELISA), and recently developed GMR magnetic analysis methods based on giant magnetoresistance and glycan analysis methods based on magnetic nanomaterials. The information obtained by these methods is the average signal and comprehensive characteristics of the vesicle population. This causes many weak but important EV glycan signals (such as glycan heterogeneity between different vesicle individuals) to be masked, which greatly hinders the application of EV glycans. While EVs glycans have shown promising potential as a novel biomarker in liquid biopsy for cancer, EVs in body fluids are actually highly complex mixtures of EV populations from different sources (including tumor tissue). Especially in the early stages of cancer, the abundance of EVs derived from cancer cells in human body fluids is low. Therefore, when analyzing EVs glycans using these methods, the signal of EVs glycans derived from cancer cells is masked by a large number of EVs glycans derived from other cells or tissues, making it impossible to effectively identify cancer-derived EVs signals. This greatly limits the application of EVs glycans in the early detection of cancer.

[0005] Therefore, there is an urgent need to develop a novel analytical method for EVs glycans to overcome the shortcomings of existing EVs glycan analysis methods and provide new technical support for the application of EVs glycans in various fields such as cancer liquid biopsy. Summary of the Invention

[0006] This invention aims to address at least one of the technical problems existing in the prior art. To this end, this invention proposes an analytical method for glycans on individual extracellular vesicles, which has superior detection sensitivity compared to holistic analysis methods (such as conventional ELISA), can fully display the differences in glycan signals among different extracellular vesicle individuals, realize the detection of glycan expression heterogeneity among extracellular vesicle individuals, and has high detection throughput and good versatility.

[0007] This invention provides a method for analyzing glycans on single extracellular vesicles, comprising the following steps:

[0008] Step S1: Capture single extracellular vesicles in the sample to be tested using magnetic nanoparticles, perform magnetic separation, and obtain a magnetic nanoparticle composite.

[0009] Step S2: Use biotin-modified lectin to affinity label the glycans on the extracellular vesicles in the magnetic nanoparticle composite, and then bind them with fluorescein-modified streptavidin to obtain fluorescently labeled magnetic composite particles.

[0010] Step S3: Use a fluorescence microscope to acquire image data and fluorescence signal data of the fluorescently labeled magnetic complex particles, and determine the degree of glycan expression on the extracellular vesicles based on the fluorescence intensity of a single fluorescently labeled magnetic complex particle.

[0011] The analysis method according to embodiments of the present invention has at least the following beneficial effects:

[0012] (1) The method of the present invention uses nano-sized magnetic particles as the manipulation medium. The sample preparation (EV capture and fluorescent labeling) can be carried out in centrifuge tubes. The operation is simple and does not require special experimental skills. In addition, the method of the present invention uses magnetic nanoparticles as the medium for EV fixation. The sample only needs to be dropped onto the cover glass substrate, and the EV is fixed on the observation substrate by the adhesion of the magnetic nanoparticles on the substrate. There is no need for time-consuming and laborious substrate modification.

[0013] (2) The method of the present invention has good repeatability, low sample requirement, and the sample operation volume can be freely adjusted; moreover, the method of the present invention is based on the reference positioning of magnetic particles of nanoscale size, and the number of sample particles in a single field of view can be as high as 10,000 or more, which has the advantage of high detection throughput.

[0014] (3) The method of the present invention has high detection sensitivity and the detection limit is significantly lower than that of the overall analysis method (such as the traditional ELISA method). It is more sensitive to the detection performance of EV glycans. Furthermore, the EV glycan information obtained by the method of the present invention is more specific and refined, which can fully reflect the heterogeneity of glycan characteristics among different EV particles.

[0015] (4) The entire operation process of the method of the present invention does not require special experimental instruments, devices, or reagents, and does not involve the preparation of complex microfluidic chips, resulting in low detection costs and good economic efficiency. In addition, the signal acquisition of the method of the present invention can be performed using a conventional fluorescence microscope, making the operation simple.

[0016] In some embodiments of the present invention, in step S1, the specific method for capturing individual extracellular vesicles in the sample to be tested includes: mixing the magnetic nanoparticles with the sample to be tested, wherein the total amount of the magnetic nanoparticles is 10 times or more the total amount of extracellular vesicle particles in the sample to be tested.

[0017] In some embodiments of the present invention, the total amount of magnetic nanoparticles is 10 to 15 times the total amount of extracellular vesicle particles in the sample to be tested, preferably 10 to 12 times, and more preferably 10 times.

[0018] By adjusting the total number of magnetic nanoparticles and the total number of extracellular vesicle particles in the sample to be tested, it is possible to ensure that no more than one extracellular vesicle is captured on the MNP@PDA particle, which facilitates the subsequent detection of fluorescence signals from individual extracellular vesicles.

[0019] In some embodiments of the present invention, the magnetic nanoparticles are core-shell structures composed of magnetic core particles and functional outer shells.

[0020] In some embodiments of the present invention, the magnetic core particles comprise iron oxide.

[0021] In some embodiments of the present invention, the functional shell comprises polydopamine.

[0022] In some embodiments of the present invention, the average particle size of the magnetic nanoparticles ranges from 100 to 300 nm. Preferably, it is 100 to 200 nm, and more preferably, it is 150 nm.

[0023] When the particle size of magnetic nanoparticles is too large, their dispersion in aqueous media is poor, and they are prone to rapid natural sedimentation (<5 minutes), which seriously affects the effective capture of EVs in the solution by magnetic nanoparticles.

[0024] However, when the particle size of magnetic nanoparticles is too small, it is not convenient for conventional fluorescence microscopy to effectively identify magnetic nanoparticles in subsequent detection processes.

[0025] In some embodiments of the present invention, the magnetic nanoparticles are polydopamine-coated magnetic nanoparticles (MNP@PDA).

[0026] In some embodiments of the present invention, the method for preparing the polydopamine-coated magnetic nanoparticles (MNP@PDA) includes:

[0027] Step S11: In a solvent, sodium acetate, sodium citrate and ferric chloride are mixed and reacted to obtain magnetic nanocore particles;

[0028] Step S12: Mix the magnetic core particles with a polydopamine solution with a concentration of 0.05-0.2 mg / mL and react to obtain the final product.

[0029] In some embodiments of the present invention, in step S11, the temperature of the reaction is 180-220°C, preferably 200°C.

[0030] In some embodiments of the present invention, in step S11, the reaction time is 8 to 12 hours.

[0031] In some embodiments of the present invention, in step S12, the mixing reaction time is 2 to 6 hours.

[0032] In some embodiments of the present invention, in step S1, the extracellular vesicles in the sample to be tested originate from cell or tissue secretion.

[0033] In some embodiments of the present invention, in step S1, the method for obtaining extracellular vesicles in the sample to be tested includes at least one of ultracentrifugation, differential centrifugation, density gradient centrifugation, precipitation, ultrafiltration, size exclusion chromatography, immunoassay, tangential flow separation, and low-pressure dialysis filtration.

[0034] In some embodiments of the present invention, in step S1, the extracellular vesicles in the sample to be tested are obtained by ultra-fast cryogenic centrifugation, specifically: the sample to be tested is centrifuged at 8000-12000g for 20-40 minutes, the supernatant is taken, and then the supernatant is centrifuged at 80000-120000g for 100-150 minutes to obtain the sample.

[0035] In some embodiments of the present invention, in step S2, the lectin includes at least one of the following: concanavalin A, lentil lectin, pea lectin, *Dictyophora indica* lectin, *Vitex negundo* lectin, wheat germ lectin, tomato lectin, potato lectin, datura lectin, succinic wheat germ lectin, Ghana seed lectin II, erythrocyte lectin, leukocyte lectin, castor bean lectin I, *Erythrina variegata* lectin, bromelain lectin, peanut lectin, hyacinth bean lectin, soybean lectin, broad bean lectin, Ghana seed lectin I, and elderberry lectin.

[0036] In some embodiments of the present invention, in step S2, the fluorescein includes at least one of isothiocyanate, rhodamine, tetramethylrhodamine, allophycocyanin, polydinoflavin chlorophyll protein, phycoerythrin, propidium iodide, CY3, CY5, and CY7.

[0037] In some embodiments of the present invention, step S3, which involves acquiring image data and fluorescence signal data of the fluorescently labeled magnetic composite particles using a fluorescence microscope, specifically includes:

[0038] The fluorescently labeled magnetic composite particles are dispersed in a buffer solution, then an appropriate amount is placed on the surface of a hydrophilic glass slide, left to stand, covered with a coverslip, and placed under the fluorescence microscope to collect data.

[0039] In some embodiments of the present invention, the hydrophilic glass slide is made of at least one of ultra-white glass, quartz, and borosilicate glass; preferably, the thickness of the hydrophilic glass slide is 0.13 to 0.22 mm.

[0040] In some embodiments of the present invention, in step S3, the fluorescence microscope includes at least one of a fluorescence microscope and a total internal reflection fluorescence microscope.

[0041] In some embodiments of the present invention, the extracellular vesicles include at least one of exosomes, microvesicles, apoptotic bodies, and cancer bodies.

[0042] Other features and advantages of the invention will be set forth in the description which follows, and will be apparent in part from the description, or may be learned by practicing the invention. Attached Figure Description

[0043] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0044] Figure 1 This is a schematic diagram of the analytical method for polysaccharides on single extracellular vesicles according to the present invention.

[0045] Figure 2 These are scanning electron microscope (SEM) images of the MNP particles and MNP@PDA particles of the present invention, wherein A is an SEM image of the MNP particles and B is an SEM image of the MNP@PDA particles.

[0046] Figure 3 This is a size distribution diagram of the particles in the mother liquor of MNP@PDA particles in this invention.

[0047] Figure 4 These are transmission electron microscope (TEM) images of the EVs particles and the MNP@PDA-EV composite of the present invention, where C is the TEM image of the EVs particles and D is the TEM image of the MNP@PDA-EV composite.

[0048] Figure 5 This is a size distribution diagram of the A549 EV particles of the present invention.

[0049] Figure 6 The images show fluorescence microscopic observations of the MNP@PDA particles and the MNP@PDA particles after capturing EVs, as presented in this invention. A is an image of the MNP@PDA carrier (no signal); B is an image of the MNP@PDA after capturing EVs (green fluorescence signal). The substrate used for microscopic imaging was a regular glass slide, and the scale bar was 20 μm.

[0050] Figure 7 The images show the fluorescence intensity results of the MNP@PDA group and the MNP@PDA-EV group of this invention. C is the stacking distribution of single particle fluorescence intensity of the MNP@PDA group (without EVs) and the MNP@PDA-EV group (with EVs); D is the statistical distribution of single particle fluorescence of the Control group and the MNP@PDA-EV group.

[0051] Figure 8The graph shows the signal comparison analysis results of the method of the present invention and the ELISA method. In the graph, A represents the relative signal intensity of the method of the present invention and the ELISA method at different EV concentrations; B represents the average value of the single particle fluorescence signal intensity obtained by the method of the present invention and the relative signal value of the ELISA method at different EV concentrations. All values ​​are normalized to the maximum relative signal value of each method.

[0052] Figure 9 This is an infographic of EVs glycans obtained using the method described in this embodiment of the invention.

[0053] Figure 10 This is an infographic of EVs glycans obtained using the comparative method of this invention. Detailed Implementation

[0054] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.

[0055] The terms "preferred," "more preferably," etc., used in this invention refer to embodiments of the invention that provide certain beneficial effects under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. Furthermore, the description of one or more preferred embodiments does not imply that other embodiments are unavailable, nor is it intended to exclude other embodiments from the scope of this invention.

[0056] When a numerical range is disclosed herein, the range is considered continuous and includes the minimum and maximum values ​​of the range, as well as every value between the minimum and maximum values. Furthermore, when the range refers to integers, it includes every integer between the minimum and maximum values ​​of the range. Additionally, when multiple ranges are provided to describe a feature or characteristic, the ranges may be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges to which they are incorporated.

[0057] In the description of this invention, the reference to terms such as "one embodiment," "some embodiments," "illustrative embodiment," "example," "specific example," or "some examples," etc., means that a specific feature or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example.

[0058] In this embodiment of the invention, the room temperature is 25±5℃.

[0059] Unless otherwise specified in the examples, the procedures should be performed under standard conditions or conditions recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all commercially available products.

[0060] Analytical workflow for glycans on single extracellular vesicles

[0061] The specific procedure for analyzing polysaccharides on single extracellular vesicles of the present invention is as follows: Figure 1 As shown, it mainly includes the following steps:

[0062] Step S1: Use functionalized magnetic nanoparticles (MNP@PDA) to capture extracellular vesicles (EVs) in the test sample. The total amount of MNP@PDA particles is ten times the total amount of EV particles. Based on the Poisson distribution principle, ensure that the vast majority of MNP@PDA particles capture no more than one EV. The magnetic nanoparticle-EV composite obtained after magnetic separation is denoted as MNP@PDA-EV.

[0063] Step S2: The MNP@PDA-EV complex particles are surface-sealed using a blocking solution. After sealing, magnetic separation is performed to remove excess blocking solution. Biotin-modified lectin is used to affinity-label the glycans on the EV particles in the MNP@PDA-EV complex. After magnetic separation, fluorescently labeled streptavidin is used to bind to the lectin molecules, utilizing the specific binding interaction between streptavidin and biotin. The fluorescently labeled MNP@PDA-EV complex is then washed and magnetically separated, and redispersed in solution to obtain a homogeneous solution of fluorescently labeled magnetic complex particles.

[0064] Step S3: Add the homogeneous solution of fluorescently labeled magnetic composite particles to a hydrophilic glass slide substrate. After the particles settle and adsorb onto the slide surface, cover with another coverslip and seal the slide. Use a fluorescence microscope to photograph the particle carrier on the slide. Collect the bright field and fluorescence signals on each MNP@PDA particle carrier through microscopic imaging and image acquisition, and perform data analysis.

[0065] Example: Analytical method for polysaccharides on single extracellular vesicles

[0066] In this embodiment, extracellular vesicle samples (A549 EV) from the human non-small cell lung cancer cell line A549 were used as the analysis object. Concanavalin A (Con A) was used as the representative lectin, and streptavidin-FITC modified with fluorescein isothiocyanate conjugate was used as the fluorescent labeling molecule for the analysis of extracellular vesicle polysaccharides. The specific procedure is as follows.

[0067] (I) Capturing EVs in solution using functionalized magnetic nanoparticles (MNP@PDA)

[0068] The specific method for capturing extracellular vesicles in solution using functionalized magnetic nanoparticles (MNP@PDA) in this embodiment is as follows:

[0069] First, 5 μL of a 1 mg / mL functionalized magnetic nanoparticle (MNP@PDA) stock solution was placed in a 0.6 mL centrifuge tube. After magnetic separation, the aqueous phase was removed, and the separated solid-phase MNP@PDA particles were washed once with 50 μL of PBS solution. Then, the magnetically separated solid-phase MNP@PDA particles were mixed with 50 μL of A549 EV sample, where the total amount of MNP@PDA particles was ten times the total amount of EV particles, ensuring that most MNP@PDA particles were not captured by more than one EV. After incubation for 30 minutes, the supernatant was removed by magnetic separation to obtain the functionalized magnetic nanoparticle complex that captured EVs (denoted as MNP@PDA-EV).

[0070] In this embodiment, the functionalized magnetic nanoparticles MNP@PDA are polydopamine (PDA) coated magnetic nanoparticles with a core-shell structure. The magnetic core particles are prepared using a solvothermal method (RSC Adv., 2016, 6, 62550–62555, doi.org / 10.1039 / C6RA09344B). The specific method is as follows: 6g of sodium acetate, 1.3g of sodium citrate, 3.25g of ferric chloride, 2mL of water, and 100mL of ethylene glycol are weighed, mixed and dissolved, and then heated at 200°C for 10 hours to obtain the magnetic nanocore particles. The functional outer shell is polydopamine, which is formed through the polymerization reaction of dopamine molecules under alkaline conditions. The method for preparing functionalized magnetic nanoparticles MNP@PDA is as follows: 3 mg of the above magnetic core particles are weighed and dispersed in a dopamine alkaline composite solution (containing 50 mL of water, 50 mg of dopamine, and 400 μL of 28% ammonia water), and the mixture is allowed to stand at room temperature for 4 hours to obtain functionalized magnetic nanoparticles MNP@PDA. The average particle size can be between 100 and 300 nm.

[0071] In this embodiment of the invention, the magnetic separation process uses a commercially available high-powered magnet (20 mm in diameter and 5 mm in thickness). During the magnetic separation operation, a 0.6 ml centrifuge tube containing magnetic nanoparticles is placed on the magnet. After the magnetic particles are fully adsorbed and clustered under the action of magnetic force, the supernatant solution is removed before proceeding with subsequent operations.

[0072] In this embodiment, the total amount of EV particles can be obtained by analyzing a nanoparticle tracking analyzer (ZetaView PMX120). First, the nanoparticle tracking analyzer is used to detect the particle concentration of the extracellular vesicle sample to obtain the number of EV particles in a unit volume of solution, i.e., the EV particle concentration. Then, by multiplying the EV particle concentration by the volume of the EV sample taken, the total amount of EV particles in the corresponding volume of EV solution can be calculated.

[0073] Furthermore, in this embodiment, setting the total number of MNP@PDA particles to ten times the total number of EV particles ensures that the vast majority of MNP@PDA particles capture no more than one EV. This is calculated using the Poisson distribution formula: when the total number of MNP@PDA particles is 10 times the total number of EV particles (i.e., λ = 0.1), the number of particles with ≤1 EV per MNP@PDA particle accounts for 99.53% of the total number of particles; at 9 times (λ = 0.111), it is 99.42%; and at 8 times (λ = 0.125), it is 99.28%. In this invention, setting the amount of magnetic particles to ten times the amount of EV particles (i.e., λ = 0.1) ensures that the vast majority of magnetic particles capture no more than one EV.

[0074] The morphology of the functionalized magnetic nanoparticles MNP@PDA prepared above was characterized by scanning electron microscopy (SEM), and the results are as follows: Figure 2 As shown in Figures A and B, the results indicate that the surface smoothness of the particles improved after coating, suggesting that PDA was successfully coated onto the MNP surface. Further characterization of the particle size distribution in the resulting MNP@PDA particle mother liquor was performed using a ZetaView nanoparticle tracking analyzer (ZetaView PMX120), and the results are shown in Figures B. Figure 3 As shown, the average particle size of the MNP@PDA particles obtained by the present invention is approximately 150 nm.

[0075] In this embodiment, the EV in the A549 EV sample is secreted by human non-small cell lung cancer cells A549. However, in other embodiments of the present invention, the EV sample may be secreted by cells or tissues, and its sources include, but are not limited to, cell culture supernatant, blood, urine, saliva, tears, and other bodily fluids; the nomenclature of the EV sample includes, but is not limited to, small EV, large EV, exosome, microvesicle, apoptotic body, and cancer body.

[0076] In this embodiment, the A549 EV sample was collected using ultracentrifugation, specifically by differential centrifugation of the solution containing EV particles. After centrifugation at 10,000 g for 30 minutes, the supernatant was collected, and then centrifuged again at 100,000 g for 120 minutes to obtain the EV precipitate. Here, g represents the acceleration due to gravity. The EV sample obtained by ultracentrifugation in this invention is directly used for subsequent glycan analysis. In other embodiments of this invention, the EV sample can be collected using methods including, but not limited to, differential centrifugation, density gradient centrifugation, polymer-based precipitation, ultrafiltration, size exclusion chromatography, immunoassay, tangential flow separation, and low-pressure dialysis filtration.

[0077] The obtained A549 EV sample and the MNP@PDA particles after EV capture were characterized by transmission electron microscopy (TEM), and the results are as follows: Figure 4 As shown, the A549 EVs sample obtained by this invention exhibits a typical vesicle structure, while the MNP@PDA particles that capture EVs show an aggregated state. The MNP@PDA particles and the EVs particles they capture are clearly visible, indicating that the MNP@PDA particles can effectively capture EVs. Furthermore, the particle size distribution and particle concentration of the EVs sample were characterized using a ZetaView nanoparticle tracking analyzer (ZetaView PMX120). Figure 5 As shown in the figure, the results indicate that the average size of EVs particles is 110 nm.

[0078] (II) Biotin-modified lectin affinity labeling

[0079] The specific steps for affinity labeling of glycans on EV particles in the MNP@PDA-EV complex using biotin-modified lectins in this embodiment are as follows:

[0080] The surface of the obtained MNP@PDA-EV particles was blocked with a 1% bovine serum albumin (BSA) solution for 1 hour. After blocking, the supernatant was removed by magnetic separation to obtain solid particles. Then, 50 μL of lectin Con A solution with a mass concentration of 5 μg / mL was added and incubated for 30 minutes to allow lectin Con A to specifically bind to the EV glycan structure. After magnetic separation, 50 μL of FITC-modified streptavidin with a mass concentration of 2.5 mg / mL was added and incubated for 30 minutes. Streptavidin-FITC was bound to lectin Con A by the specific affinity of streptavidin for biotin. After removing the supernatant by magnetic separation, excess streptavidin-FITC molecules were washed away with 100 μL of PBS solution. After removing the washing solution by magnetic separation, the obtained solid particles were redispersed uniformly in 30 μL of PBS solution.

[0081] In embodiments of the present invention, the blocking solution can be a bovine serum albumin solution with a mass fraction of 1% to 5% or a commercially available rapid blocking solution (such as NcmBlot blocking buffer), which has a considerable blocking effect. Furthermore, the lectin used in this embodiment is modified with biotin, and based on the fact that different lectins can target and bind to different glycan structures, it can be replaced with the appropriate lectin according to actual needs during the actual detection process. Commonly used lectins include concanavalin A (ConA), lentil lectin (LCA), pea lectin (PSA), *Dictyophora indica* lectin (AAL), vitex lectin I (UEA-I), wheat germ lectin (WGA), tomato lectin (LEL), potato lectin (STL), datura stramonium lectin (DSL), and succinylated wheat germ lectin. The following are examples of biotin-modified lectins: WGA, Ghana seed lectin II (GSL-II), erythrocyte lectin (PHA-E), leukocyte lectin (PHA-L), ricin lectin I (RCA-I), coral tree lectin (ECL), jackfruit lectin (jacalin), peanut lectin (PNA), hyacinth bean lectin (DBA), soybean lectin (SBA), fava bean lectin (VVL), Ghana seed lectin I (GSL-I), and elderberry lectin (SNL). Except for the lectins mentioned above, all other biotin-modified lectins can be used with the method of this invention.

[0082] In the embodiments of the present invention, the streptavidin used is modified with fluorescent molecules. Theoretically, there are no restrictions on the types of fluorescent molecules, including but not limited to FITC, Rhodamine, TRITC, APC, polydinoflavin chlorophyll protein, phycoerythrin, propidium iodide, CY3, CY5, CY7, etc. In this embodiment, the streptavidin fluorescent molecule conjugate used is FITC-modified streptavidin.

[0083] (III) Fluorescence Microscopy Data Acquisition

[0084] Take 10 μL of homogeneous particulate solution and drop it onto a commercial ultra-white glass cover glass with a thickness of 0.17 ± 0.01 mm. The magnetic nanoparticles loaded with EV can settle and adhere to the surface of the glass within 5 minutes. After covering the liquid with another cover glass to seal the liquid surface, images and fluorescence signal data can be acquired using a wide-field fluorescence microscope.

[0085] In this embodiment, the glass slide used is a commercially available glass slide with a hydrophilic surface treatment. Theoretically, its thickness and material are unlimited, with a thickness including but not limited to 0.13 to 0.22 mm. The slide material includes, but is not limited to, ultra-clear glass, quartz, and borosilicate glass. In this embodiment, a commercially available ultra-clear glass coverslip with a thickness of 0.17 ± 0.01 mm is used. Furthermore, during image data acquisition, a wide-field fluorescence microscope is used in this example to capture images of the magnetic nanoparticle carrier in both bright-field and fluorescence channels. However, in actual acquisition, the microscope type is not limited to a wide-field fluorescence microscope; a total internal reflection fluorescence microscope can also be used. During microscopic observation, the sample is positioned using magnetic particles that are easily observed in bright field, and multi-channel imaging is performed to obtain bright-field and fluorescence images of the sample.

[0086] High-throughput image signal acquisition of EV-loaded magnetic particles was performed using a fluorescence microscope. The number of target particles acquired in each field of view (FOV) of the microscope can be freely adjusted. In this embodiment, the number of target particles in each FOV is greater than 10,000. During the analysis, the number of EVs analyzed is unlimited and can be freely adjusted. In addition, theoretically, there are no restrictions on the type of image processing software used for processing and exporting the particle carrier images acquired by the fluorescence microscope, including but not limited to ImageJ / Fiji and ZEN Blue 3.5. In this embodiment, ZEN Blue 3.5 analysis software was used to perform bright-field identification of nanoparticle carriers and fluorescence value analysis of EVs loaded on the particles in the acquired multi-channel images, and the obtained data values ​​were converted and exported.

[0087] Images of the MNP@PDA carrier and images of the MNP@PDA after EV capture, acquired using the fluorescence microscopy data acquisition method of this embodiment, are shown below. Figure 6 As shown, A is an image of the MNP@PDA carrier (no signal); B is an image of MNP@PDA after EV capture (green fluorescence signal). The microscope images were taken on ordinary glass slides with a scale bar of 20 μm. The results show that wide-field fluorescence microscopy can effectively identify MNP@PDA particles in bright field, and the particles are monodisperse. The fluorescence channel images indicate that pure MNP@PDA particles have no obvious fluorescence signal; while the EV-loaded MNP@PDA particles show a significant green fluorescence signal in the fluorescence channel.

[0088] Furthermore, the signal distributions of pure MNP@PDA particles and EV-loaded magnetic nanoparticles MNP@PDA-EV (MNP@PDA-EV group) are as follows: Figure 7As shown, A represents the packing distribution of fluorescence intensity of single particles in the pure MNP@PDA particle group and the MNP@PDA-EV group; B represents the statistical distribution of fluorescence intensity of single particles in the pure MNP@PDA particle group and the MNP@PDA-EV group. The results show that the fluorescence signal intensity distribution of pure MNP@PDA particles without EV loading is mainly concentrated in the range of 0–165, while the fluorescence signal distribution of EV-loaded magnetic nanoparticles (MNP@PDA-EV) ranges from 0–2541. The fluorescence signals of some particles in the MNP@PDA-EV sample are much stronger than those of pure MNP@PDA particles, indicating that these signals originate from the EVs captured by the MNP@PDA particles. The strength of these signals reflects the expression level of the ConA-targeted glycans on the EV particles. Furthermore, from... Figure 7 As can be seen from the distribution diagram of B, the distribution range of the pure MNP@PDA particle signal and the magnetic nanoparticle MNP@PDA-EV carrying EV almost does not overlap, indicating that the method of the present invention can effectively realize the detection and acquisition of glycan information on a single EV particle.

[0089] Comparative example: ELISA method

[0090] This comparative example used a standard ELISA method to detect extracellular vesicle samples (A549 EV) from the human non-small cell lung cancer A549 cell line. The specific procedure is as follows:

[0091] Place 50 μL of EV sample into a 96-well microplate. After incubation for 30 minutes, remove the EV solution and add 100 μL of 1% BSA solution to block the plate. After 1 hour of blocking, remove the blocking solution and add 50 μL of a 5 μg / mL biotin-modified lectin solution. Incubate for 30 minutes to allow the lectin molecules to target and bind to the glycan structure on the EV. Then remove the lectin supernatant and add 50 μL of 2.5 mg / mL FITC-modified streptavidin solution. Incubate for 30 minutes to allow the enzyme molecules to bind to the lectin molecules through the specific affinity of streptavidin for biotin. Wash the microplate with 100 μL of PBS solution to remove free fluorescent molecules that have not bound to the lectin molecules. Finally, add 50 μL of PBS solution and collect the fluorescence signal using a microplate reader.

[0092] Example 1: Comparison of sensitivity test results

[0093] This detection example uses concanavalin A (Con A) as the lectin and streptavidin modified with fluorescein isothiocyanate conjugate as the fluorescent labeling molecule. The detection methods of the present invention and the comparative examples were used to detect extracellular vesicle samples from the human non-small cell lung cancer A549 cell line and to acquire fluorescence microscopy data. The detection limits of the two different detection methods were examined. The signal definition of the method in the present invention is... Figure 7 The total number of particles in the non-overlapping portions of the MNP@PDA-EV group and the MNP@PDA group in group B was calculated. The signal from the ELISA method was the conventional fluorescence signal. Both signals were normalized to the relative signal maximum value of each method.

[0094] The statistical results of the relative signal intensity of the method in this embodiment and the comparative ELISA method are as follows: Figure 8 As shown in A, this indicates that the detection limit using the method of the present invention can be as low as 10. 7 The detection limit of 10 cells / mL is 10 under the same conditions using the ELISA method. 9 The detection limit of the method of the present invention is 100 times that of the ELISA method, indicating that the analytical method for glycans on single extracellular vesicles proposed in this invention has superior detection sensitivity compared with the whole cell analysis method.

[0095] Furthermore, regarding the data obtained above ( Figure 8 A) in the above process is averaged by summing the fluorescence signals of all particles and then dividing by the total number of particles. Further normalization is then performed using the maximum signal value. The result is as follows: Figure 8 As shown in B, the relative signal value curve of the method of the present invention has a high degree of overlap with the relative signal value curve of the ELISA method. This conversely illustrates that the overall testing method represented by ELISA can only provide the average signal of glycans on different EV particles, but the method of the present invention can perform fine segmentation and detection of EV population information at the level of a single EV.

[0096] Example 2: Comparison of results for detecting heterogeneity in glycan expression

[0097] This detection example uses 22 lectins targeting different glycan structures. The glycans of A549 EVs samples were analyzed using the method of this embodiment and the comparative ELISA method. The relevant signals of the 22 lectins were collected one by one. After data processing and summarization, the glycan spectrum was obtained by plotting the spectrum using Graphpad Prism software.

[0098] The results are as follows Figure 10 As shown, this indicates that for each lectin, the ELISA method ( Figure 10The glycan spectra acquired by C and D in the present invention can only show a single average signal value of the EV sample, while the single EV glycan spectra acquired by the method of the present invention ( Figure 9 Figures A and B can show the distribution range of glycan signals in detail, fully demonstrating the differences in glycan signals among different EV vesicle individuals, revealing the heterogeneity of glycan expression among EV vesicle individuals, indicating that the method of the present invention can perform refined identification and analysis of EV glycans, and also proving the universality of the method of the present invention for the analysis of different glycan structures.

[0099] In summary, this invention provides an analytical method for glycans on single extracellular vesicles (EVs). It uses functional nanoparticles as the manipulation medium for EVs, integrating EV capture, manipulation, and localization functions to achieve the analysis of glycan signals on single EVs. The main advantages are as follows:

[0100] (1) The method of the present invention uses nano-sized magnetic particles as the manipulation medium. The sample preparation (EV capture and fluorescent labeling) can be carried out in centrifuge tubes. The operation is simple and does not require special experimental skills. In addition, the method of the present invention uses magnetic nanoparticles as the medium for EV fixation. The sample only needs to be dropped onto the cover glass substrate, and the EV is fixed on the observation substrate by the adhesion of the magnetic nanoparticles on the substrate. There is no need for time-consuming and laborious substrate modification.

[0101] (2) The method of the present invention has good repeatability, low sample requirement, and freely adjustable sample operation volume; and the method of the present invention is based on the reference positioning of magnetic particles of nanoscale size, and the number of sample particles in a single imaging field can be as high as 10,000 or more, with high throughput; at the same time, the detection limit of the method of the present invention is significantly lower than that of holistic analysis methods such as the traditional ELISA method, and the detection performance of EV glycans is more sensitive. Moreover, the EV glycan information obtained by the method of the present invention is more specific and refined, and can fully reflect the heterogeneity of glycan characteristics among different EV particles.

[0102] (3) The entire operation process of the method of the present invention does not require special experimental instruments, devices, or reagents, and does not involve the preparation of complex microfluidic chips, resulting in low detection costs and good economic efficiency. In addition, the signal acquisition of the method of the present invention can use a conventional fluorescence microscope, eliminating the need for high-end and expensive microscopic imaging devices such as super-resolution microscopes and total internal reflection microscopes, making the operation simpler.

[0103] The embodiments of the present invention have been described in detail above. However, the present invention is not limited to the above embodiments. Within the scope of knowledge possessed by those skilled in the art, various changes can be made without departing from the spirit of the present invention. Furthermore, the embodiments of the present invention and the features thereof can be combined with each other unless otherwise specified.

Claims

1. A method for analyzing glycans on single extracellular vesicles, characterized in that, Includes the following steps: Step S1: Capture individual extracellular vesicles in the sample to be tested using magnetic nanoparticles, and perform magnetic separation to obtain a magnetic nanoparticle composite; wherein, the magnetic nanoparticles are core-shell structures composed of magnetic core particles and functional shells, the magnetic core particles are iron oxide, and the functional shells are polydopamine; the average particle size of the magnetic nanoparticles ranges from 100 to 300 nm; the total number of magnetic nanoparticles is 10 to 15 times the total number of extracellular vesicle particles in the sample to be tested; Step S2: Use biotin-modified lectin to affinity label the glycans on the extracellular vesicles in the magnetic nanoparticle composite, and then bind them with fluorescein-modified streptavidin to obtain fluorescently labeled magnetic composite particles. Step S3: A homogeneous solution of the fluorescently labeled magnetic complex particles is dropped onto a hydrophilic glass slide substrate. After the fluorescently labeled magnetic complex particles settle and adsorb onto the surface of the slide, another coverslip is placed on top and the slide is sealed. Image data and fluorescence signal data of the fluorescently labeled magnetic complex particles are collected using a fluorescence microscope. The degree of polysaccharide expression on the extracellular vesicles is determined based on the fluorescence intensity of a single fluorescently labeled magnetic complex particle. The analytical method described is used for purposes other than disease diagnosis or treatment.

2. The analytical method according to claim 1, characterized in that, In step S1, the specific method for capturing individual extracellular vesicles in the sample to be tested includes: mixing the magnetic nanoparticles with the sample to be tested.

3. The analytical method according to claim 1, characterized in that, In step S1, the extracellular vesicles in the sample to be tested originate from cell or tissue secretion.

4. The analytical method according to claim 1, characterized in that, In step S2, the lectin includes at least one of the following: concanavalin A, lentil lectin, pea lectin, *Dictyophora indica* lectin, *Vitex negundo* lectin I, wheat germ lectin, tomato lectin, potato lectin, datura lectin, succinic wheat germ lectin, Ghana seed lectin II, erythrocyte lectin, leukocyte lectin, castor bean lectin I, *Erythrina variegata* lectin, bromelain lectin, peanut lectin, *Lysimachia foetida* lectin, soybean lectin, broad bean lectin, Ghana seed lectin I, and elderberry lectin.

5. The analytical method according to claim 1, characterized in that, In step S2, the fluorescein includes at least one of isothiocyanate, rhodamine, tetramethylrhodamine, allophycocyanin, polydinoflavin chlorophyll protein, phycoerythrin, propidium iodide, CY3, CY5, and CY7.

6. The analytical method according to claim 1, characterized in that, In step S3, the fluorescence microscope includes at least one of a wide-field fluorescence microscope and a total internal reflection fluorescence microscope.

7. The analytical method according to any one of claims 1 to 6, characterized in that, The extracellular vesicles include at least one of exosomes, microvesicles, apoptotic bodies, and cancer bodies.

Citation Information

Patent Citations

  • Analysis of exosomes and methods of diagnosing cancer

    CN109490528A

  • Magnetic analysis of extracellular vesicular glycans

    CN114845811A